Literature DB >> 17187019

Plasma nerve growth factor (NGF) and inflammatory cytokines (IL-6 and MCP-1) in young and adult subjects with Down syndrome: an interesting pathway.

Massimiliano M Corsi1, Giada Dogliotti, Francesca Pedroni, Elisa Palazzi, Paolo Magni, Martina Chiappelli, Federico Licastro.   

Abstract

OBJECTIVES: Down's syndrome (DS) is the most frequent chromosomal aberration in men and it is invariably associated with mental retardation.
MATERIAL AND METHODS: Plasma levels of nerve growth factor (NGF), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) from non demented DS subjects of three different age-cohorts (2-14 years; 20-50 yrs; >60 yrs) and healthy controls were measured. No clinical and sub-clinical inflammation was apparent in DS patients.
RESULTS: Plasma levels of NGF were higher in children, adult and old DS subjects than in controls. However, a significant age-related decrease of NGF levels was present in DS subjects. Serum levels of IL-6 and MCP-1 were also increased in DS children and adults, but not in older DS patients.
CONCLUSIONS: High levels of circulating NGF might protect DS from clinical complications of atherosclerosis. However, the striking decrement of peripheral NGF levels with advancing age may predispose DS to clinical manifestation of dementia after adulthood.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17187019

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  7 in total

1.  Age-related changes in plasma levels of BDNF in Down syndrome patients.

Authors:  Giada Dogliotti; Emanuela Galliera; Federico Licastro; Massimiliano M Corsi
Journal:  Immun Ageing       Date:  2010-01-25       Impact factor: 6.400

Review 2.  The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives.

Authors:  Fiorenza Stagni; Renata Bartesaghi
Journal:  Front Cell Neurosci       Date:  2022-05-11       Impact factor: 6.147

3.  Apigenin as a Candidate Prenatal Treatment for Trisomy 21: Effects in Human Amniocytes and the Ts1Cje Mouse Model.

Authors:  Faycal Guedj; Ashley E Siegel; Jeroen L A Pennings; Fatimah Alsebaa; Lauren J Massingham; Umadevi Tantravahi; Diana W Bianchi
Journal:  Am J Hum Genet       Date:  2020-10-23       Impact factor: 11.025

4.  Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.

Authors:  Carla M Startin; Nicholas J Ashton; Sarah Hamburg; Rosalyn Hithersay; Frances K Wiseman; Kin Y Mok; John Hardy; Alberto Lleó; Simon Lovestone; Lucilla Parnetti; Henrik Zetterberg; Abdul Hye; André Strydom
Journal:  Alzheimers Res Ther       Date:  2019-03-21       Impact factor: 6.982

Review 5.  Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?

Authors:  Laura Reiche; Patrick Küry; Peter Göttle
Journal:  Cells       Date:  2019-12-07       Impact factor: 6.600

6.  Altered pro-inflammatory and anti-inflammatory plasma cytokines levels in children with Down's syndrome: A meta-analysis.

Authors:  Nitu Nigam; Prithvi K Singh; Neena Raizada; Balendra P Singh; Shalini Tripathi; Monica Agrawal; Harish Gupta; Sharad Singh; Ghizal Fatima; Sanjay K Nigam; Shailendra K Saxena
Journal:  J Family Med Prim Care       Date:  2021-11-05

7.  Neuroinflammatory Markers in the Serum of Prepubertal Children with Down Syndrome.

Authors:  Luigi Tarani; Valentina Carito; Giampiero Ferraguti; Carla Petrella; Antonio Greco; Massimo Ralli; Marisa Patrizia Messina; Debora Rasio; Enrica De Luca; Carolina Putotto; Paolo Versacci; Mauro Ceccanti; Marco Fiore
Journal:  J Immunol Res       Date:  2020-03-23       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.